FinnCap reissued their buy rating on shares of Cello Group plc (LON:CLL) in a research report sent to investors on Wednesday. They currently have a GBX 132 ($1.78) price target on the stock.

Cello Group plc (CLL) opened at 132.00 on Wednesday. The company’s 50 day moving average price is GBX 124.95 and its 200 day moving average price is GBX 126.43. The stock’s market cap is GBX 115.03 million. Cello Group plc has a 12 month low of GBX 94.60 and a 12 month high of GBX 140.00.

WARNING: “Cello Group plc (CLL) Given Buy Rating at FinnCap” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at

Cello Group plc Company Profile

Cello Group plc is a United Kingdom-based healthcare and consumer strategic marketing company. The Company is engaged in providing market research, consulting and direct marketing services. The Company operates through two segments: Cello Health and Cello Signal. The Cello Health Division provides market research, consulting and communications services principally to the Company’s pharmaceutical and healthcare clients.

Receive News & Ratings for Cello Group plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cello Group plc and related companies with Analyst Ratings Network's FREE daily email newsletter.